Erasca (ERAS) Faces FDA Trial Pause and New Patent Win Is Its RAS Strategy Balanced?

Simply Wall St.01-11

In recent days, the FDA placed a partial clinical hold on Erasca’s Phase 1 BOREALIS-1 trial of its pan-KRAS inhibitor ERAS-4001 after adverse events were observed, pausing parts of a key early-stage ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602795553?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-01-11 14:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602795553","market":"hk","top_or_hot":-1,"title":"Erasca (ERAS) Faces FDA Trial Pause and New Patent Win Is Its RAS Strategy Balanced?","media":"Simply Wall St.","content":"<div>\n<p>In recent days, the FDA placed a partial clinical hold on Erasca’s Phase 1 BOREALIS-1 trial of its pan-KRAS inhibitor ERAS-4001 after adverse events were observed, pausing parts of a key early-stage ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eras/erasca/news/erasca-eras-faces-fda-trial-pause-and-new-patent-win-is-its\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Erasca (ERAS) Faces FDA Trial Pause and New Patent Win Is Its RAS Strategy Balanced?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nErasca (ERAS) Faces FDA Trial Pause and New Patent Win Is Its RAS Strategy Balanced?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-11 14:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eras/erasca/news/erasca-eras-faces-fda-trial-pause-and-new-patent-win-is-its><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In recent days, the FDA placed a partial clinical hold on Erasca’s Phase 1 BOREALIS-1 trial of its pan-KRAS inhibitor ERAS-4001 after adverse events were observed, pausing parts of a key early-stage ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eras/erasca/news/erasca-eras-faces-fda-trial-pause-and-new-patent-win-is-its\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eras/erasca/news/erasca-eras-faces-fda-trial-pause-and-new-patent-win-is-its","article_id":"2602795553","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eras/erasca/news/erasca-eras-faces-fda-trial-pause-and-new-patent-win-is-its","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602795553","pubTimestamp":1768113054,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In recent days, the FDA placed a partial clinical hold on Erasca’s Phase 1 BOREALIS-1 trial of its pan-KRAS inhibitor ERAS-4001 after adverse events were observed, pausing parts of a key early-stage cancer study.\nThis setback comes alongside Erasca securing a long-dated U.S. patent for its pan-RAS molecular glue ERAS-0015, underscoring a contrasting mix of safety uncertainty and potential longer-term competitive protection.\nWe’ll now examine how the FDA’s partial clinical hold on ERAS-4001...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ERAS":"Erasca, INC.","BK4539":"次新股"},"translate_title":"Erasca(ERAS)面临FDA试验暂停并赢得新专利其RAS战略平衡吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ERAS":1.5},"content_text":"In recent days, the FDA placed a partial clinical hold on Erasca’s Phase 1 BOREALIS-1 trial of its pan-KRAS inhibitor ERAS-4001 after adverse events were observed, pausing parts of a key early-stage cancer study. This setback comes alongside Erasca securing a long-dated U.S. patent for its pan-RAS molecular glue ERAS-0015, underscoring a contrasting mix of safety uncertainty and potential longer-term competitive protection. We’ll now examine how the FDA’s partial clinical hold on ERAS-4001 reshapes Erasca’s investment narrative and risk-reward profile. The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.AdvertisementWhat Is Erasca's Investment Narrative?To own Erasca today, you really have to believe that its RAS-focused pipeline can translate into clinically meaningful cancer drugs before the cash runway runs out, and that the current valuation fairly reflects the binary nature of that effort. The recent FDA partial clinical hold on the Phase 1 BOREALIS-1 trial of ERAS-4001 directly affects one of the company’s most important 2026 catalysts by injecting safety uncertainty and timing risk into a core program, even as the long-dated U.S. patent on ERAS-0015 strengthens potential competitive positioning if the science plays out. With no revenue, ongoing annual net losses above US$120,000,000 and a share price that has already moved very sharply over the past year, the big question now is whether the benefit of the patent win and broader pan-RAS enthusiasm can offset the higher perceived risk around ERAS-4001. However, there is one emerging risk around trial safety and timelines that investors should not ignore.\n\nThe valuation report we've compiled suggests that Erasca's current price could be inflated.Exploring Other PerspectivesERAS 1-Year Stock Price Chart The Simply Wall St Community’s two fair value estimates cluster tightly between US$4.96 and about US$5.44, reflecting relatively aligned expectations. Against that, the new FDA partial clinical hold on ERAS-4001 underlines how quickly sentiment and key 2026 catalysts can shift, which is exactly why it helps to weigh several different viewpoints before deciding how this story might fit in your portfolio.Explore 2 other fair value estimates on Erasca - why the stock might be worth 27% less than the current price!Build Your Own Erasca NarrativeDisagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Erasca research is our analysis highlighting 3 important warning signs that could impact your investment decision.Our free Erasca research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Erasca's overall financial health at a glance.Seeking Other Investments?Every day counts. These free picks are already gaining attention. See them before the crowd does:Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.Outshine the giants: these 28 early-stage AI stocks could fund your retirement.Find companies with promising cash flow potential yet trading below their fair value.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Erasca might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602795553","isCrawlerRequest":true}